BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Calendar//CN-US Event Research//ZH
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Calendar
X-WR-CALDESC:Market-moving event research, reminders and post-event review.
BEGIN:VEVENT
UID:evt-fda-compounding-peptides-adcom-july-2026@catalyst-calendar.local
DTSTAMP:20260720T200527Z
DTSTART:20260723T120000Z
DTEND:20260723T123000Z
SUMMARY:FDA复方药房顾问委员会讨论多类肽类原料纳入503A Bulks List
DESCRIPTION:FDA 7月23-24日会议将讨论多类肽类原料是否纳入503A Bulks List，可能影响复方药房、远程医疗、代谢健康和抗衰老相关商业模式监管预期。\\nImpact score: 66\\nExpected: 委员会建议可能改变部分肽类复方药合规边界，并影响消费医疗平台对相关产品线的监管风险定价。\\nAffected: HIMS(theme\, mixed\, score 70)\; XBI(etf\, mixed\, score 52)\; LLY(peer\, mixed\, score 48)\; NVO(peer\, mixed\, score 48)\\nSources: FDA advisory committee calendar: https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026\\nInformation only. Not investment advice.
URL:https://0.0.0.0:3000/?event=evt-fda-compounding-peptides-adcom-july-2026
CATEGORIES:policy\,US\,FDA\,compounding\,peptides\,telehealth
SEQUENCE:0
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:Review catalyst preview: FDA复方药房顾问委员会讨论多类肽类原料纳入503A Bulks List
END:VALARM
BEGIN:VALARM
TRIGGER:PT24H
ACTION:DISPLAY
DESCRIPTION:Complete post-event review: FDA复方药房顾问委员会讨论多类肽类原料纳入503A Bulks List
END:VALARM
END:VEVENT
END:VCALENDAR